Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
With less than two months left in office, the Biden administration said Tuesday it would seek to let Medicare pay for weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound ...
Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...
The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Senator Bernie Sanders (I-VT), for example, stated that “unless Medicare demands that Novo Nordisk and Eli Lilly substantially reduce the prices for these anti-obesity drugs, Medicare premiums for all ...
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...
The prices were compared to 11 other countries{beacon} Health Care Health Care   The Big Story Medicare negotiated prices ...
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...
including Medicare, do not offer reimbursement to treat obesity alone. The new approval is for people with moderate to severe obstructive sleep apnea who are also living with obesity. Eli Lilly ...